Loading...
Market
What revenue rank will AstraZeneca's obesity pill achieve by end of 2026?
2
Resolution / Starting Odds
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Not in Top 50 • 25%
AstraZeneca's financial reports and industry analysis
Story
AstraZeneca's obesity pill shows 5.8% weight loss in early trial, safe and tolerable for type-2 diabetes patients, licensed from Eccogene for $2 billion
Nov 4, 2024, 06:15 PM
AstraZeneca has announced promising results from its experimental obesity pill, which showed a 5.8% reduction in body weight during an early-stage clinical trial. The company reported that the medication was well-tolerated by patients, including those with type-2 diabetes. The trial indicated that side effects were consistent with the GLP-1 drug class, and the pill was deemed safe for use. This medication was licensed from China's Eccogene for up to $2 billion, highlighting AstraZeneca's commitment to expanding its portfolio in weight-loss treatments.
View original story
Similar markets
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Leader in the sector • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Sanofi • 25%
Other • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%